A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Life Spine Announces First Surgical Cases of DYNA-LINK® Titanium With Barb Fixation

Life Spine notes DYNA-LINK Titanium Stand-Alone Anterior Lumbar System is a zero-profile, stand-alone device that offers surgeons a safe and reliable alternative to 360˚ fusion procedures. In addition to providing immediate fixation, multiple footprints, heights, screw options, and now barbs are available to accommodate various patient anatomies and pathologies to promote fusion.

“DYNA-LINK Titanium Barb offering provides an integrated supplemental fixation system that allows for a less invasive direct anterior approach. Barbs are preloaded within the inserter for the titanium implant, permitting seamless deployment of fixation for the cage and eliminating the need for angulated instruments,” said Dr. Ali Mesiwala of the DISC Sports & Spine Center in Newport Beach, California. “This potentially reduces surgical time and incision size and provides an ideal option to treat my patients in both the outpatient and inpatient setting.”

DYNA-LINK Titanium Features and Benefits:

  • Stand-Alone Device *barbs require supplemental fixation
  • Streamlined Barb Delivery Instrumentation
  • Osseo-Loc® Surface Technology
  • 37˚ to 45˚ Screw Angulation
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy